Taysha Gene Therapies highlights Phase 1/2 REVEAL trial data for TSHA-102 in Rett syndrome
TSHA•Taysha Gene Therapies said it will present encore data on TSHA-102 at the Child Neurology Society meeting on Oct. 14-17, 2026. Results from the REVEAL Part A trial showed functional improvements across multiple domains in pediatric and older patients, with an acceptable safety profile.
1. Encore presentations
Taysha Gene Therapies announced encore presentations on TSHA-102 for Rett syndrome at the Child Neurology Society meeting on Oct. 14-17, 2026. The clinical findings were previously presented at the 2026 International Rett Syndrome Foundation scientific meeting.
2. Trial findings
The updates draw from the REVEAL Part A Phase 1/2 trial and point to functional improvements across multiple domains in pediatric and older patients, alongside an acceptable safety profile. TSHA-102 is Taysha's lead central nervous system gene therapy program.
